We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

62 hedge funds and large institutions have $167M invested in Kiniksa Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

26% more capital invested

Capital invested by funds: $132M → $167M (+$34.9M)

15% more funds holding

Funds holding: 54 → 62 (+8)

2.3% less ownership

Funds ownership: 81.05% → 78.75% (-2.3%)

Holders
62
Holders Change
+8
Holders Change %
+14.81%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
25
Reduced
11
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Ameriprise
Ameriprise
Minnesota
+$4.15M
2
GTC
Ghost Tree Capital
New York
+$3.04M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.69M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$2.07M
5
Millennium Management
Millennium Management
New York
+$1.82M

Top Sellers

1
DM
Deerfield Management
New York
-$10.8M
2
VMI
VHCP Management II
New York
-$4.6M
3
VMI
VHCP Management III
New York
-$2.36M
4
Victory Capital Management
Victory Capital Management
Texas
-$2.02M
5
BlackRock
BlackRock
New York
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$31M – – –
ACH
2
ArrowMark Colorado Holdings
Colorado
$25.3M +$2.07M +238,153 +12%
HA
3
HHLR Advisors
Cayman Islands
$21M +$246K +28,266 +2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$13.3M +$304K +34,942 +3%
Ameriprise
5
Ameriprise
Minnesota
$12.7M +$4.15M +477,940 +71%
BlackRock
6
BlackRock
New York
$10.5M -$1.47M -169,462 -15%
SI
7
Sofinnova Investments
California
$10.2M – – –
Hudson Bay Capital Management
8
Hudson Bay Capital Management
Connecticut
$4.87M +$2.69M +310,000 +238%
Alyeska Investment Group
9
Alyeska Investment Group
Illinois
$4.29M +$216K +24,806 +7%
Citadel Advisors
10
Citadel Advisors
Florida
$4.05M -$20.3K -2,333 -0.6%
GTC
11
Ghost Tree Capital
New York
$3.87M +$3.04M +350,000 New
BC
12
Boxer Capital
California
$3.21M – – –
State Street
13
State Street
Massachusetts
$2.49M -$36.9K -4,245 -2%
Millennium Management
14
Millennium Management
New York
$2.32M +$1.82M +209,421 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.11M +$214K +24,617 +15%
FFM
16
Fairmount Funds Management
Pennsylvania
$1.83M +$1.44M +165,318 New
Bank of America
17
Bank of America
North Carolina
$1.72M +$174K +19,993 +15%
Northern Trust
18
Northern Trust
Illinois
$1.64M -$133K -15,305 -9%
Morgan Stanley
19
Morgan Stanley
New York
$1.5M +$239K +27,518 +25%
Squarepoint
20
Squarepoint
New York
$1.34M +$799K +91,926 +318%
PPA
21
Parametric Portfolio Associates
Washington
$651K +$63.3K +7,285 +14%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$637K +$501K +57,627 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$512K -$52K -5,989 -11%
BFM
24
Boothbay Fund Management
New York
$487K +$382K +44,000 New
OAM
25
Oxford Asset Management
United Kingdom
$442K +$347K +39,991 New
1
2 3

KNSA Hedge Fund Activity: Q4 2019 in Review

62 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2019, worth a combined $167M — up 26% from $132M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new KNSA positions and 10 closed out — a net gain of 8 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was Ameriprise, adding an estimated $4.15M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.8M sold.

  • 62 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $167M of Kiniksa Pharmaceuticals stock for Q4 2019, up 26% quarter-over-quarter.
  • 18 funds opened new Kiniksa Pharmaceuticals positions in Q4 2019 and 10 closed out, a net change of +8 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2019 was Ameriprise, an estimated $4.15M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2019 was Deerfield Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q4 2019.